Disease Area

Expert pathologist Fred Plapp offers a summary of the virus causing COVID-19, its effects, and the pandemic’s evolving status

"Biogen revitalizes hope for Alzheimer’s therapy, but their work highlights why we still need greater selectivity."

Could modulation of fibroblast growth factor 21 translate into a new treatment for non-alcoholic fatty liver disease?

Combining metabolomics and DNA sequencing could be the key to discovering new inborn errors of metabolism in children.

How sex-dependent differences in molecular mechanisms could underpin men and women’s distinct experiences of chronic neuropathic pain.

New evidence points to the safety – and benefits – of immune checkpoint therapy in HIV-positive cancer patients

Could manipulation of micro-RNA cross-talk between astrocytes and neuronal cells yield a new therapeutic avenue for ALS?

How inhibiting both polyamine synthesis (with DFMO) and uptake (with new small molecule AMXT 1501) could delay tumor development.

The latest advances in translational medicine – condensed into 20-second servings.

Three leading lights in the neuro-oncology sphere explain what inspired them, how the field has evolved, and what challenges lie ahead.